Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03800602 · ClinicalTrials.gov registry record · Phase 2
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT03800602 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 29 participants.
The verdict
NCT03800602, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase II trial studies how well nivolumab and metformin work in treating patients with microsatellite stable (MSS) stage IV colorectal cancer that has not responded to previous treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Metformin is an antidiabetic drug that and may reduce the risk of colorectal cancer development in patients. Giving nivolumab and metformin may work better in treating patients with refractory microsatellite metastatic colorectal cancer.
Interventions
- DRUG Metformin
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2021-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03800602
The ClinicalTrials.gov registry entry for NCT03800602 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.
NCT03800602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03800602 about?
NCT03800602 is a clinical study titled "Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer". This phase II trial studies how well nivolumab and metformin work in treating patients with microsatellite stable (MSS) stage IV colorectal cancer that has not responded to previous treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the c...
What is the current status of trial NCT03800602?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2019-01-15. Estimated completion is 2021-09-04.
What interventions are being tested in trial NCT03800602?
The interventions under investigation include: Metformin (DRUG), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03800602?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.